Greenwich LifeSciences, Inc.’s GLSI share price has dipped by 5.17%, which has investors questioning if this is right time to ...

STAFFORD, Texas, April 03, 2025 (GLOBE NEWSWIRE) -- Greenwich LifeSciences, Inc. (Nasdaq: GLSI) (the "Company"), a clinical-stage biopharmaceutical company focused on its Phase III clinical trial ...

GREENWICH LIFESCIENCES ($GLSI) is expected to release its quarterly earnings data on Monday, April 14th after market close, per Finnhub. Analysts are expecting ...

STAFFORD, Texas, April 03, 2025 (GLOBE NEWSWIRE) -- Greenwich LifeSciences, Inc. (Nasdaq: GLSI) (the "Company"), a clinical-stage biopharmaceutical company focused on its Phase III clinical trial, ...

These two general immune response findings, immune response at baseline and increasing immune response over time, were also observed in the Phase IIb clinical trial for HLA-A*02 only patients. These ...

Greenwich LifeSciences (NASDAQ:GLSI) added ~23% in the premarket on Wednesday after the company posted preliminary immune response data from a Phase 3 clinical trial for GLSI-100, a vaccine ...

Greenwich LifeSciences (GLSI), a clinical-stage biopharmaceutical company focused on its Phase III clinical trial, FLAMINGO-01, which is ...

Greenwich LifeSciences, Inc. STAFFORD, Texas, April 02, 2025 (GLOBE NEWSWIRE) -- Greenwich LifeSciences, Inc. (Nasdaq: GLSI) (the "Company"), a clinical-stage biopharmaceutical company focused on ...

Cryo-Cell International Inc (CCEL) is expected to report $0.00 for 1Q. Digital Ally Inc (DGLY) is expected to report for 4Q.

Greenwich LifeSciences (NASDAQ:GLSI) added ~23% in the premarket on Wednesday after the company posted preliminary immune response data from a Phase 3 clinical trial for GLSI-100, a vaccine designed ...

Novo Nordisk is licensing a drug called LX9851 from Lexicon Pharmaceuticals for up to $75 million in upfront and near-term ...